Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Dec 22, 2020

Pfizer-BioNTech Shot Likely Beats New Covid Strain, EMA Says

STOCKS IN THIS STORY
Goenka Business & Finance Ltd.
--
Cosco (India) Ltd.
--
Pritika Auto Industries Ltd
--
SAB Events & Governance Now Media Ltd.
--
BSE Healthcare
--

The new strain of Covid-19 that emerged in the U.K. probably isn't different enough from earlier ones to elude Pfizer Inc. and BioNTech SE's vaccine, Europe's health regulator said.

The antibody response seen from the shot shouldn't be compromised by the effects of mutations in the new strain, Marco Cavaleri, chairman of the European Medicines Agency's pandemic taskforce, said in a press briefing on Monday. Health authorities would start to be worried “if we see multiple mutations, particularly in the spike protein,” Cavaleri said.

“Even if we don't have yet full confirmation, it is very likely that the vaccine will retain protection against this new variant,” Cavaleri said. The U.K. started its vaccination campaign on Dec. 8. By Monday, some 500,000 people had gotten their first dose of the vaccine, Health Minister Matt Hancock tweeted.

How Worrisome Is This U.K. Virus Variant?: Sam Fazeli

The regulator's optimism comes as Europe closes its U.K. borders and London faces an emergency lockdown to keep the mutant strain from spreading. The new variant appears to spread much more quickly than previous strains in circulation, U.K. health authorities have warned, though it does not seem to be more lethal.

Although coronaviruses generally don't mutate as quickly as viruses responsible for seasonal flu, scientists have been tracking small changes throughout the pandemic. The U.K. variant raised worries because samples collected from patients showed that the new strain was fueling a disproportionate number of new infections.

Why the U.K.‘s Mutated Coronavirus Is Fanning Worries: QuickTake

The spike protein Cavaleri referenced is key because it's the target for many of the Covid-19 vaccines in development -- including the Pfizer-BioNTech and Moderna Inc. shots that have already won emergency authorization in the U.S.

The European Commission approved Pfizer's vaccine on Monday, clearing the path for immunizations to start in Europe before the end of the year.

©2020 Bloomberg L.P.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search